Literature DB >> 8385438

Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.

P Greally1, M J Hussein, A J Cook, A P Sampson, P J Piper, J F Price.   

Abstract

It is postulated that a vigorous host inflammatory response in the cystic fibrosis lung contributes to lung injury. Tumour necrosis factor-alpha (TNF-alpha) may play a part in that process and in the generation of leukotrienes. Therefore, the relationships between sputum TNF-alpha, leukotriene concentration, and lung function abnormalities in 16 children with cystic fibrosis were investigated. Each subject provided sputum samples and performed spirometry. TNF-alpha was measured by enzyme linked immunosorbent assay; individual leukotrienes were separated using high performance liquid chromatography and quantified by radioimmunoassay. The geometric mean concentration of TNF-alpha was 129.7 pg/ml and 95% confidence interval 48.2 to 348.3. Mean (SEM) leukotriene B4 (LTB4) was 97.8 (22.9) pmol/g and total cysteinyl leukotrienes were 60.9 (14.8) pmol/g. Mean (SD) forced expiratory volume in one second (FEV1) of the group was 53 (15)% of predicted and forced vital capacity (FVC) was 65 (14)% of predicted. There was a significant positive correlation between TNF-alpha and both LTB4 and the total cysteinyl leukotriene sputum content. An inverse relationship existed between TNF-alpha and FEV1 and FVC. Moreover, a negative correlation was observed between sputum LTB4 and FEV1 and FVC. These results suggest that TNF-alpha and the leukotrienes may participate in the airways inflammation and airflow obstruction observed in cystic fibrosis subjects and support the hypothesis that TNF-alpha upregulates the 5-lipoxygenase pathway in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385438      PMCID: PMC1793872          DOI: 10.1136/adc.68.3.389

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  20 in total

1.  Recombinant human tumour necrosis factor (rTNF)2 enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the Ca2+ ionophore A23187.

Authors:  R Roubin; P P Elsas; W Fiers; A J Dessein
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

Review 2.  Leukotrienes and airway responses.

Authors:  J M Drazen; K F Austen
Journal:  Am Rev Respir Dis       Date:  1987-10

3.  Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome.

Authors:  A B Millar; N M Foley; M Singer; N M Johnson; A Meager; G A Rook
Journal:  Lancet       Date:  1989-09-23       Impact factor: 79.321

4.  Plasma tumour necrosis factor alpha in cystic fibrosis.

Authors:  D Norman; J S Elborn; S M Cordon; R J Rayner; M S Wiseman; E J Hiller; D J Shale
Journal:  Thorax       Date:  1991-02       Impact factor: 9.139

5.  Tumor necrosis factor. Alpha and beta subtypes appear in circulation during onset of sepsis-induced lung injury.

Authors:  S K Leeper-Woodford; P D Carey; K Byrne; J K Jenkins; B J Fisher; C Blocher; H J Sugerman; A A Fowler
Journal:  Am Rev Respir Dis       Date:  1991-05

6.  Tumor necrosis factor-alpha priming of phospholipase A2 activation in human neutrophils. An alternative mechanism of priming.

Authors:  S A Bauldry; C E McCall; S L Cousart; D A Bass
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

7.  Inhibition of tumour necrosis factor alpha (TNF-alpha)-induced neutrophil respiratory burst by a TNF inhibitor.

Authors:  A Ferrante; B Hauptmann; P Seckinger; J M Dayer
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

8.  Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock.

Authors:  D R Tabor; S K Burchett; R F Jacobs
Journal:  Proc Soc Exp Biol Med       Date:  1988-04

9.  Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF).

Authors:  A Meager; S Parti; H Leung; E Peil; B Mahon
Journal:  Hybridoma       Date:  1987-06

10.  Leukotrienes in the sputum and urine of cystic fibrosis children.

Authors:  A P Sampson; D A Spencer; C P Green; P J Piper; J F Price
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

View more
  34 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

3.  TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis.

Authors:  Sabina Schmitt-Grohé; Frank Stüber; Malte Book; Joachim Bargon; Thomas O Wagner; Christian Naujoks; Ralf Schubert; Michael J Lentze; Stefan Zielen
Journal:  Lung       Date:  2006 Mar-Apr       Impact factor: 2.584

Review 4.  Use of modulators of airways inflammation in patients with CF.

Authors:  Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 5.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

6.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

Review 7.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

8.  Estrogen receptor-alpha as a drug target candidate for preventing lung inflammation.

Authors:  Elisabetta Vegeto; Salvatore Cuzzocrea; Concetta Crisafulli; Emanuela Mazzon; Angelo Sala; Andreè Krust; Adriana Maggi
Journal:  Endocrinology       Date:  2009-12-01       Impact factor: 4.736

9.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

10.  Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis.

Authors:  Amanda J Stolarz; Ryan A Farris; Charla A Wiley; Catherine E O'Brien; Elvin T Price
Journal:  Clin Transl Sci       Date:  2015-08-10       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.